While it seems like ages ago there was a time when Abbott (NYSE: ABT) had the hottest product in continuous glucose monitoring. Yet thanks to numerous mistakes made by management the Navigator took forever to receive FDA approval allowing Dexcom (NASDAQ: DXCM) to establish a firm grip on the CGM market. Given that the FDA still has not approved the FreeStyle Libre we’re beginning to wonder whether history is repeating itself.
Let’s be honest the Libre has surpassed expectations and continues to gather growing usage overseas. Yet even with this growing international acceptance the product is still not . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.